中重度银屑病患者年龄与生物制剂生存率的队列研究
结果显示16-24岁患者因无效停用TNF抑制剂风险更高,而55岁及以上患者因不良事件停用生物制剂风险更高。
要点
- 16-24岁患者因无效停用TNF抑制剂风险较45-54岁参考组升高(aHR 1.30,95%CI 1.10-1.55)。
- 55-64岁患者因不良事件停用TNF抑制剂和IL-12/IL-23抑制剂风险升高。
- ≥75岁患者因不良事件停用四类生物制剂风险均升高。
核心结论
- 16-24岁银屑病患者更可能因无效停用TNF抑制剂。
- 55岁及以上患者更可能因不良事件停用生物制剂。
研究设计与样本
- 按治疗起始年龄分为16-24、25-34、35-44、45-54、55-64、65-74和≥75岁组,以45-54岁为参考。
主要发现
- 16-24岁组因无效停用TNF抑制剂风险较参考组升高(aHR 1.30,95%CI 1.10-1.55)。
- 55-64岁组因不良事件停用TNF抑制剂和IL-12/IL-23抑制剂风险升高(aHR 1.33,95%CI 1.13-1.56;aHR 1.34,95%CI 1.03-1.75)。
- 65-74岁组因不良事件停用TNF抑制剂、IL-12/IL-23抑制剂和IL-17抑制剂风险升高(aHR 1.89,95%CI 1.54-2.31;aHR 2.00,95%CI 1.47-2.73;aHR 1.69,95%CI 1.08-2.64)。
- ≥75岁组因不良事件停用四类生物制剂风险均升高。
临床怎么用
- 对年轻患者选择TNF抑制剂时需关注疗效可能不足。
- 对55岁及以上患者使用生物制剂时应加强不良事件监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current management of psoriasis does not differentiate between younger and older patients in selecting the safest and/or most effective biologic. OBJECTIVES: To explore the effect of age at treatment initiation in response to biologics in patients with moderate-to-severe psoriasis in the UK and Eire. METHODS: Data from patients registered in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) from 2007 to 2024 on a first course of tumour necrosis factor (TNF), interleukin (IL)-12/IL-23, IL-17 and IL-23 inhibitors with at least 6 months' follow-up were included. Patients aged ≥ 16 years at registration were organized into the following cohorts: 16-24 years, 25-34 years, 35-44 years, 45-54 years, 55-64 years, 65-74 years and ≥ 75 years. The 45-54 years age group was used as the reference cohort. Biologic survival was defined as the time between treatment initiation to its discontinuation associated with ineffectiveness or the occurrence of adverse events (AEs). Adjusted hazard ratios (aHR) with 95% confidence intervals (CIs) was estimated using a flexible parametric model to compare discontinuing treatment between the age groups. Each model included exposure (biologic class), effect modifier (age groups), interaction terms, baseline demographics and clinical and disease severity covariates. RESULTS: In total, 14 294 patients were included and organized into the following age groups: 16-24 years, n = 847 (5.9%); 25-34 years, n = 2502 (17.5%); 35-44 years, n = 3575 (25.0%); 45-54 years, n = 3863 (27.0%); 55-64 years, n = 2338 (16.4%); 65-74 years, n = 954 (6.8%); and ≥ 75 years, n = 215 (1.5%). The interaction effects model showed that individuals aged 16-24 years were more likely to discontinue TNF inhibitors (TNFi) due to ineffectiveness than those in the reference cohort (aHR 1.30, 95% CI 1.10-1.55). For survival associated with AEs, individuals aged 55-64 years were at higher risk of discontinuing TNFi and IL-12/IL-23 inhibitors [IL-12i/IL-23i; aHR 1.33 (95% CI 1.13-1.56) and aHR 1.34 (95% CI 1.03-1.75), respectively]; those aged 65-74 years were more likely to discontinue TNFi, IL-12i/IL-23i and IL-17 inhibitors [aHR 1.89 (95% CI 1.54-2.31), aHR 2.00 (95% CI 1.47-2.73) and aHR 1.69 (95% CI 1.08-2.64), respectively], whereas individuals aged ≥ 75 years were at higher risk of discontinuing the four biologic classes. CONCLUSIONS: Patients aged 16-24 years with psoriasis are more likely to stop TNFi due to ineffectiveness, whereas those aged ≥ 55 years are more likely to stop biologics due to AEs. These real-world findings provide important information for clinicians treating people with moderate-to-severe psoriasis across all age groups. Plaque psoriasis is a common skin disease. It affects at least 60 million people worldwide. It is associated with other medical conditions, such as psoriatic arthritis. It can affect people’s quality of life. In current practice, age is not taken into account when prescribing a type of medicine called ‘biologics’ to treat psoriasis. Older people with psoriasis, who are more likely to have other medical conditions, are often excluded from clinical trials. We looked at the effect of people’s age at treatment initiation on their response to biologics. We used data from a large register of patients with psoriasis called ‘BADBIR’. BADBIR covers the UK and Republic of Ireland. Response to treatment was measured using ‘biologic survival’. This was defined as a person stopping treatment because it was ineffective or they experienced adverse events. This study of a large number of people with psoriasis showed that some younger patients are more likely to stop taking some biologics. We also found that older people were more likely to stop biologic treatment because they experienced adverse events. The findings of this study have important implications for clinicians. Biologics are effective in older people with plaque psoriasis. However, there needs to be strict monitoring for adverse events.
引用
- Alabas OA, Mason KJ, Yiu ZZN, et al. Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Br J Dermatol. 2025. PMID: 39792925. doi:10.1093/bjd/ljaf017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。